Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KVA12.1
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Kineta
Deal Size : Undisclosed
Deal Type : Partnership
Humedix Closes Strategic Investment in US-based Kineta to Boost CMO Business
Details : Humedix has secured certain exclusive distribution rights in Korea for products that are commercialized from Kineta's pipeline currently under development including KVA12.1.
Brand Name : KVA12.1
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 04, 2021
Lead Product(s) : KVA12.1
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Kineta
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?